

10/533414

JC14 Rec'd PCT/PTO 29 APR 2005

Express Mail No. EV514612465US

Date of Deposit: April 29, 2005

LMC/SLR:dm 04/27/05 6682-66957-02 378987 CGL02/0396WO01 A55-522.1

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Brent Daniel Rogers,
Lawrence E. Fosdick, and John A. Bohlmann

Application No. Currently unknown

Filed: Herewith

Confirmation No. Currently unknown

For: N-ACETYL-D-GLUCOSAMINE (NAG)
SUPPLEMENTED FOOD PRODUCTS
AND BEVERAGES

Examiner: Not yet assigned

Art Unit: Not yet assigned

Attorney Reference No. 6682-66957-02

MAIL STOP PCT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(2)

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Copies of United States patents and United States published patent applications do not have to be provided to the Patent Office (37 C.F.R. 1.98(a)(2)(ii)). Copies of unpublished U.S. applications do not have to be provided, as long as the application is available on PAIR, as this requirement of 37 C.F.R. § 1.98(a)(2)(iii) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on October 19, 2004 (1287 OG 163). Applicants will provide copies of such patents or applications upon request.

Applicants filed this Information Disclosure Statement (“IDS”) within three months of the date of entry of the national stage as set forth in § 1.491 in an international application. As a

10/533414

JC14 Rec'd PCT/PTO 29 APR 2005

Express Mail No. EV514612465US

Date of Deposit: April 29, 2005

PATENT


LMC/SLR:dm 04/27/05 6682-66957-02 378987 CGL02/0396WO01 A55-522.1

result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of this IDS is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By 
Sheree Lynn Rybak, Ph.D.
Registration No. 47,913

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

cc: Docketing

10/533414

MAILED APR 29 2005
Express Mail No. EV514612465US

Date of Deposit: April 29, 2005

LMC/SLR:dm 04/27/05 6682-66957-02 369563

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	6682-66957-02
	Application Number	Currently unknown
	Filing Date	April 29, 2005
	First Named Inventor	Rogers
	Art Unit	Not yet assigned
	Examiner Name	Not yet assigned

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		2003/0134825	07/17/2003	Bahoshy
		2003/0138543	07/24/2003	Bahoshy
		2003/0170374	9/11/2003	Bahoshy
		2002/0160459	10/31/2002	Berry et al.
		6,225,493	5/1/2001	Prakash et al.
		6,432,929	8/13/2002	Stone

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		WIPO	WO 01/93847 A2	13.12.2001	The Procter & Gamble Company
		WIPO	WO 03/013435 A2	20.02.2003	Cargill, Incorporated

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	

EXAMINER SIGNATURE:	DATE CONSIDERED:
------------------------	---------------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.